Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Deargen logo — AI-First Pharmatech Company. We are exploring sequence-based...

Deargen

AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.

Founded 2016 Korea South Korea South 11 employees Series B Total: $23.00B AI, Biotechnology +1

General Information

Company Name Deargen
Founded Year 2016
Location Korea South Korea South
Employees 11
Industries AI, Biotechnology, Machine Learning
Funding Stage Series B
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Project Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Deargen. To contact Deargen, visit deargen.me.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Deargen compare?

A PDF of Deargen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Deargen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Deargen

Deargen, founded in 2016, positions itself as a pioneer in the intersection of AI and pharmaceuticals. This AI-First Pharmatech Company focuses on revolutionizing drug discovery and development through sequence-based AI solutions. Headquartered in Korea South, the company leverages advanced AI, particularly transformer technology, to overcome traditional challenges in drug research, such as the dependency on 3D protein structures.

Their innovative approach positions them as a potential game-changer in the AI, Biotechnology, and Machine Learning industries. A standout feature of Deargen is its end-to-end AI platform that accelerates drug discovery while cutting costs, making it attractive for investors seeking impactful ventures.

In their latest funding round, Deargen secured a KRW20.00B Series B investment on February 24, 2022, with backing from prominent investors such as Korea Development Bank, TS Investment, Hana Ventures, The Wells Investment, Inc., and Nvestor (Korea). This financial support highlights significant confidence in their innovative potential and market readiness.

Business keywords: AI-driven drug discovery, sequence-based drug development, transformer technology in pharmaceuticals, Hit/Lead compound discovery, end-to-end AI solution, biotechnology innovation, genome analysis service, deep learning in pharma, computational chemistry, medicinal chemistry, target discovery, lead optimization, AI in healthcare, pharmatech innovation, drug design and development

Services & Products

AI Platform for Drug Discovery
New Drug Development
Molecular Optimization
Target Affinity Prediction
Toxicity-Centered Drug Design

Target Customers

Pharmaceutical Companies Biotech Firms Medical Research Institutions Drug Development Organizations AI-Driven Healthcare Providers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B KRW20.00B 5
Korea Development Bank TS Investment Hana Ventures
Korea Development Bank, TS Investment +3
24 Feb 2022
Seed Round KRW3.00B 3
TS Investment Hana Ventures
TS Investment, Hana Ventures +1
26 Oct 2020
Non Equity Assistance Undisclosed 1
TIPS Program
01 Nov 2018

Deargen Alternatives & Competitors

View All Alternatives
Deargen vs
CrystalsFirst
CrystalsFirst Germany

Turning Insights Into Medicines

Non Equity Assistance
18 employees
AI, Biotechnology
Deargen vs
iktos
iktos France

Artificial intelligence for new drug design

Series A
85 employees
AI, Biotechnology
Deargen vs
Pharmacelera
Pharmacelera Spain

Mine enhanced chemical space. Design superior candidates

Seed
28 employees
Biotechnology, Information Technology
Also compare with: Deargen vs Standigm Standigm View all alternatives

FAQ About Deargen

AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.
Deargen was founded in 2016.
Deargen is headquartered in Korea South.
Deargen operates in AI, Biotechnology and Machine Learning. Its work centres on AI-driven drug discovery, sequence-based drug development, transformer technology in pharmaceuticals and Hit/Lead compound discovery. Its customers include Pharmaceutical Companies, Biotech Firms and Medical Research Institutions.
Deargen has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Project Based and Licensing.
Deargen has approximately 11 employees.
Deargen has completed 3 funding rounds, raising a total of $23.00B. The latest funding stage is Series B.
Deargen offers: AI Platform for Drug Discovery, New Drug Development, Molecular Optimization, Target Affinity Prediction, Toxicity-Centered Drug Design.
Top alternatives and competitors to Deargen include CrystalsFirst, iktos, Pharmacelera, Standigm, Ro5. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deargen and CrystalsFirst are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Deargen, https://bouncewatch.com/company/deargen, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes